Allison Jarstad, DO
Ophthalmology · Medford, ORNPI 1265729081
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,735 of the $8,735 with a category attached, or 65.7%. 24 manufacturers reported payments, led by Glaukos Corporation at 40.9% of the total. Reporting peaked in 2020 at $3,263 and has fallen 81.9% since, to $592 in 2025. Among ophthalmology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $60.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$4K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$509
- Rxsight Inc$451
- Aerie Pharmaceuticals, Inc.$411
- Biotissue Holdings Inc.$342
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$3,00034%
- Food & beverage$5,73566%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 12 | $3,577 |
| Alcon | 16 | $1,136 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $509 |
| Rxsight Inc | 11 | $451 |
| Aerie Pharmaceuticals, Inc. | 17 | $411 |
| Biotissue Holdings Inc. | 9 | $342 |
| Sight Sciences, Inc. | 5 | $332 |
| AbbVie(2 entities) | 9 | $291 |
| Novartis | 13 | $270 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $187 |
| Nova Eye, Inc. | 2 | $172 |
| Bausch & Lomb Americas Inc. | 9 | $160 |
| Ivantis, Inc | 1 | $149 |
| NEW World Medical,inc. | 9 | $132 |
| Bioventus LLC | 1 | $115 |
| Kala Pharmaceuticals, Inc. | 1 | $112 |
| Sun Pharmaceutical Industries Inc. | 6 | $111 |
| AstraZeneca | 1 | $98 |
| Dompe US, Inc. | 3 | $61 |
| Tarsus Pharmaceuticals, Inc. | 2 | $38 |
| Amgen | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Omeros Corporation | 1 | $20 |
| Alimera Sciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent Trabecular Micro-Bypass Stent System$3,000
- Rhopressa$362
- Rocklatan$362
- TEARCARE SYSTEM$285
- AcrySof IQ PanOptix$279
- Hydrus Microstent$279
- iStent inject W$272
- KXL System$216
- Photrexa$216
- AcrySof IQ VIVITY IOL$149
- AcrySof IQ PanOptix UV IOL$142
- RXSIGHT CONTACT LENS$140
- RXSIGHT INJECTOR CARTRIDGE$140
- RXSIGHT INJECTOR HANDPIECE$140
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$140
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$140
- RESTASIS$125
- Prokera$121
- AmnioGraft$121
- Exogen$115
How this compares
$8,735 in reported general payments places this provider in the 90th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 407 | $19,131 |
| RestasisCyclosporine | 11 | $6,971 |
| Ketorolac Tromethamine | 335 | $4,678 |
| Ofloxacin | 360 | $3,983 |
| Latanoprost | 94 | $1,859 |
| ValacyclovirValacyclovir Hcl | 26 | $915 |
| Timolol Maleate | 55 | $797 |
| Brimonidine Tartrate | 27 | $734 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 56 | $615 |
| Doxycycline Hyclate | 17 | $577 |
| Atropine Sulfate | 11 | $570 |
| ErythromycinErythromycin Base | 47 | $507 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $291 | $6,97111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in Medford
- Poorav PatelMedford$10K
- Yujen WangMedford$4K
- Adam AufderheideMedford$3K
- David HuangCorvallis$67K
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Bart AdamsPendleton$17K
- Richard WeleberPortland$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.